Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Orion Oyj Share Issue/Capital Change 2013

May 20, 2013

3232_rns_2013-05-20_d3b148ae-6b59-4532-8c9a-c6b49bc68575.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Disclosure 307361

Orion - Company Announcement

225,000 Orion A-shares converted into B-shares

ORION CORPORATION STOCK EXCHANGE RELEASE 20 MAY 2013 at 09.15 a.m. EEST In accordance with Section 3 of the Articles of Association of Orion Corporation, 225,000 A-shares have been converted into 225,000 B-shares. The conversion has been entered into the Trade Register on 20 May 2013. The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 42,310,318 A-shares and 98,947,510 B-shares. Orion Corporation Olli Huotari Jari Karlson SVP, Corporate Functions CFO Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland Homepage: www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs. Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki. [HUG#1703049]